B+
Bull case
25%
Probability
Target price
$1.35
+13.4% vs current
CYPH
CypherpunkDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.90
-24.4% vs current
B-
Bear case
30%
Probability
Target price
$0.45
-62.2% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+22.1
Score
AI commentary
Primary-source context is real, but the setup now looks more like a cautious monitoring situation than a directional small-cap biotech long. The deterministic prior is neutral with low catalyst density and elevated uncertainty, which fits the evidence: the March 2026 10-K confirms a major strategy pivot toward Zcash/privacy technology while keeping biotech operations in Leap, and the April 2026 8-K adds governance churn rather than a clean operating inflection [#10-K-2026-03-16] [#8-K-2026-04-10].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-30eventProxy/board refresh could sharpen strategic oversight signalHigh impact
The April 7, 2026 board retirements create a concrete governance event; the upcoming proxy and annual-meeting process should show whether the company is rebuilding the board around its hybrid privacy-tech, Zcash, and biotech profile or simply shrinking oversight capacity [#8-K-2026-04-10] [#10-K-2026-03-16].
2026-05-15catalystQ1 2026 10-Q should clarify treasury marks, cash burn, and control remediationHigh impact
The next quarterly filing is the cleanest near-term check on whether ZEC-linked balance-sheet exposure, cash usage, and remediation of the disclosed material weakness are stabilizing after the late-2025 strategy shift; this is more a monitoring catalyst than a thesis unlock [#10-K-2026-03-16].
2026-12-31catalystTreasury execution or biotech partnering could narrow the credibility gapHigh impact
Management says Cypherpunk is now centered on a Zcash-focused privacy technology strategy while biotech operations continue in Leap, and the 10-K also states it may seek additional funding or cost-sharing through financings, collaborations, or licenses. Any evidence that the company can fund operations without diluting heavily, monetize treasury strength, or secure a biotech partner would matter, but visibility is weak today [#10-K-2026-03-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology